YLYing-Ping Li

Ying-Ping Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ying-Ping Li has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    H3K4 Methylation Readers in Plants: Recognition Mechanisms and Biological Functions

    by Yingping Li, Xin Li, Xinzhuo Zhang, Hongkai Sha, Le Xue, Lijuan Gui, Jing Ji, Zheng Chen, Huijia Kang, Yi Mou

    Methylation of histone H3 at lysine 4 (H3K4me) is a key epigenetic mark in plants, governing transcriptional regulation, development, and stress adaptation. While the enzymes that deposit and remove this mark are well studied, how H3K4me signals are interpreted by reader proteins remains less understood. This review synthesizes recent advances in the molecular recognition of H3K4me states by plant reader domains, including PHD, BAH, CW, Tudor, and chromodomain modules. Unlike prior reviews that focused on writers and erasers or on stress-specific responses, we systematically examine the reader-side mechanisms, with particular emphasis on how distinct methylation states, including trimethylated (H3K4me3), dimethylated (H3K4me2), monomethylated (H3K4me1), and unmethylated H3K4, are discriminated and translated into chromatin-based outputs. These readers function as signaling hubs, integrating environmental and hormonal cues to regulate flowering, DNA repair, and stress memory, with implications for crop performance. However, fundamental gaps remain, including the identification of H3K4me1-specific readers, the structural basis for combinatorial histone mark recognition, and the evolutionary divergence of reader pathways between monocots and dicots. Our review provides a framework for understanding H3K4me reader biology and explores its potential for application in plant breeding.

  • Open Access

    High-yield synthesis of antibiotic-derived carbon dots for enhanced Achyranthes bidentata growth and in vitro bone bonding

    by Guanxiong Liu, Yihan Li, Hui Wang, Hongchen Zhu, Junli Fan, Chunyu Wan, Minghao Wang, Yan Chen, Changqian Zhou, Qun Wang, et al.

  • Preparation, Characterization and in vitro Pharmacological Evaluation of PLGA-Encapsulated Tofacitinib Nanoparticulate Drug Delivery Systems for the Treatment of Rheumatoid Arthritis

    by Yan Wang, Shuai Wen, Ying-Ping Li, Lu Sun, Hong-Kai Sha, Yao Zhao, Yi Mou, Dong-Kai Wang

    Tofacitinib (Tof), a JAK3 inhibitor, is clinically utilized for the treatment of moderate to severe rheumatoid arthritis (RA). However, long-term oral administration of Tof can lead to serious systemic toxicity and adverse effects. To mitigate its toxicity, this study prepared drug-loaded nanoparticles (NPs), PLGA@Tof, utilizing poly (lactic-co-glycolic acid) PLGA as the matrix. These NPs exhibited a particle size of 220[ ]nm, a zeta potential of −13.4[ ]mV, drug loading and encapsulation efficiency were 4.12% and 40.57%, and a smooth spherical morphology. In vitro studies demonstrated that these NPs achieved sustained release of Tof without inducing hemolytic effects; less than 50% Tof was released within 24[ ]h under [ ]H 5.0 and [ ]H 7.4 conditions. Cellular experiments revealed that the uptake rates of NPs at 1[ ]h, 2[ ]h, 4[ ]h and 8[ ]h in RAW264.7 cells were significantly higher than that of the free drug under inflammatory conditions. After 8 h of treatment with PLGA@Tof on inflammatory RAW264.7 cells, the intracellular reactive oxygen species (ROS) level was significantly lower compared to the free Tof treatment group, while the levels of TNF-[ ], IL-1 [ ] and IL-6 were also significantly reduced in the PLGA@Tof treatment group. These findings suggest that PLGA@Tof has the potential to be developed into a long-acting nanotherapeutic agent for systemic or localized injection in the treatment of RA.

  • Open Access

    Discovery of Novel Tofacitinib–ADTOH Molecular Hybridization Derivatives for the Treatment of Ulcerative Colitis

    by Yi Mou, Shuai Wen, Yan Wang, Yao Zhao, Ying-Ping Li, Hong-Kai Sha, Li-Juan Gui, Zheng-Yu Jiang, Xiang-Ming Xu

    The treatment of ulcerative colitis (UC) has been a major medical challenge due to the lack of safe and effective drugs. Molecular hybridization is a promising strategy for the development of drugs with pleiotropic activity, which has been demonstrated in a wide range of diseases. Tofacitinib has exhibited significant effects on the remission of UC, but a series of adverse effects have occurred during its clinical application. Herein, we propose to utilize a molecular hybridization strategy to link tofacitinib with a cytoprotective H2S donor (ADTOH) to obtain a series of hybridized molecules ZX-4C~ZX-6C. Among them, ZX-4C exhibited the best performance in the H2S release rate and the cytoprotective effects against dextran sulfate sodium (DSS)-induced injury. The in vivo studies showed that ZX-4C could effectively alleviate DSS-induced colitis by enhancing oxidative stress defense and reducing the inflammatory response, demonstrating that it is more potent than the parent drugs. The data from the present study support that this molecular hybridization strategy provides a promising avenue for the treatment of UC.